RCT: A single immediate dose of intravenous tenecteplase is noninferior to alteplase for the treatment of patients with acute ischemic stroke.

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

News Release: UCalgary researchers with the Calgary Stroke Program make another breakthrough in the treatment of stroke